Jay Cheng is a Senior Associate Scientist at Gilead Sciences since November 2021, with a strong background in in vivo pharmacology focused on cancer immunology, utilizing syngeneic and xenograft mouse models. Prior experience includes a role as a Senior Associate Scientist at Amgen from January 2016 to November 2021, and a Research Associate at Genentech, Inc from May 2004 to January 2016, where responsibilities included maintaining genetically modified mouse colonies and establishing in vivo models for ocular diseases. Additional experience encompasses roles at Renovis, Geron Corporation, and Connetics Corporation, where Jay Cheng contributed to research on traumatic brain injuries, stem cell applications in Parkinson's disease and cardiac models, as well as pharmacological studies of human recombinant relaxin. Jay Cheng holds a Bachelor of Science degree in Biochemistry from Stony Brook University, completed in 1996.
This person is not in the org chart
This person is not in any teams
This person is not in any offices